Publications

Explore our latest thinking in non-viral gene engineering, developments in our targeted CAR-T programs in oncology, and more. Read the latest publications, research, and presentations on our science, from cancer to rare genetic disease.

$Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) - profile$

Efficacy and Safety of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)

American Society of Hematology Annual Meeting (ASH) 2020 Oral Presentation, Virtual

C. Costello, A. D. Cohen, K. K. Patel, S. Abbas Ali, J. G. Berdeja, N. Shah, S. Ganguly, M. Kocoglu, M. Abedi, A. Deol, E. M. Ostertag, C. E. Martin, M. Ghoddusi, D. J. Shedlock, J. McCaigue, H. Namini, K. McArthur, S. Yalamanchili,M. A. Spear, T. K. Gregory

Cas-CLOVER™ Gene Editing for Allogeneic CAR-T Production

Hanson Wade CRISPR 2.0 Conference

Blair Madison, Ph.D., Senior Director, Genetic Engineering

Manufacturing Matters in CAR-T: Small Changes Can Have a Big Impact

CAR-TCR Digital Week Presentation

Eric Ostertag, M.D., PhD., Chairman & CEO

Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-BCMA-ALLo1, Is Robust, Reproducible and Highly Scalable

American Society of Hematology Annual Meeting 2019 Poster Presentation, Orlando, FL

Stacey A. Cranert, Maximilian Richter, Min Tong, Leslie Weiss, Yening Tan, Xianghong Li, Eric M. Ostertag, Julia Coronella, Devon J. Shedlock

P-BCMA-ALLo1: A Non-Viral Allogeneic anti-BCMA CAR-T Therapy With Potent Anti-Tumor Function for the Treatment of Multiple Myeloma

Annual SITC 2019 Presentation by Maximilian Richter, Ph.D., National Harbor, MD

CAR-T Clinical Trials: New Directions in Biomarkers

Annual CAR-TCR Summit 2019 Presentation by Matthew A. Spear, MD., Boston, MA

Nonviral piggyBac® and Cas-CLOVER™ Genetic Engineering Technologies for Development of Stem Cell Memory (Tscm) CAR-Ts

Annual CAR-TCR Summit 2019 Presentation by Devon J. Shedlock, PhD., Boston, MA

$Update of the P-BCMA-101-001 Phase 1 Clinical Trial: A Novel Stem Cell Memory CAR-T for Relapsed/Refractory Multiple Myeloma - profile$

Update of the P-BCMA-101-001 Phase 1 Clinical Trial: A Novel Stem Cell Memory CAR-T for Relapsed/Refractory Multiple Myeloma

Annual CAR-TCR Summit 2018 Presentation by Eric Ostertag, M.D. Ph.D., Boston, MA

P-MUC1C-101: A Stem Cell Memory CAR-T Therapy for Epithelial-Derived Solid Tumors

Annual CAR-TCR Summit 2018 Presentation by Devon Shedlock, Ph.D., Boston, MA

Manufacture of Allogeneic “Universal Donor” CAR-T Therapies Using piggyBac™ and Cas-CLOVER™

Annual CAR-TCR Summit 2018 Presentation by Burton Barnett, Ph.D., Boston, MA

PSMA-specific CAR-T Memory Stem Cell Therapy Eliminates Solid Tumors in Multiple Prostate Cancer Models

Annual CAR-TCR Summit 2018 Poster Presentation, Boston, MA

Jenessa B. Smith, Rebecca Codde, Yening Tan, Chris E. Martin, Burton E. Barnett, Srinivas Rengarajan, Eric M. Ostertag, Devon J. Shedlock

Non-Viral Engineered Human CAR-T Cells for Safe and Specific Stem Cell Transplant Conditioning

American Society of Gene and Cell Therapy Annual Meeting 2018 Poster Presentation, Chicago, IL

Nina D. Timberlake, Natalie Chen, Claire S. Koechlein, Maximilian Richter, Armenuhi Avanesyan, Nicholas Cam, Xinxin Wang, Rebecca Codde, Yening Tan, Eric M. Ostertag, Devon J. Shedlock, Julian D. Down

$Clinical Trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T Cells in Relapsed/Refractory Multiple Myeloma - profile$

Clinical Trial of P-BCMA-101 T stem cell memory (Tscm) CAR-T Cells in Relapsed/Refractory Multiple Myeloma

American Association of Cancer Research Annual Meeting 2018 Poster Presentation, Chicago, IL

K. Gregory1, J. G. Berdeja2, K. K. Patel3, S. Abbas Ali4, A. D. Cohen5, C. Costello6, E. M. Ostertag7, N. de Silva7, D. J. Shedlock7, C. Martin7, S. Rengarajan7, B. Barnett7, M. Resler7, M. A. Spear7, R. Z. Orlowski3 1Colorado Blood Cancer Inst., Denver, CO; 2Tennessee Oncology, Nashville, TN; 3MD Anderson Cancer Ctr., Houston, TX; 4Johns Hopkins Univ., Baltimore, MD; 5Abramson Cancer Ctr. Univ. of Pennsylvania, Philadelphia, PA; 6Moores Cancer Ctr., UC San Diego, San Diego, CA; 7Poseida Therapeutics, Inc., San Diego, CA, 92121

Cas-CLOVER™: A High-Fidelity Genome Editing System for Safe and Efficient Modification of Cells for Immunotherapy

2018 Precision CRISPR Congress Poster Presentation, Boston, MA

Xianghong Li, Xinxin Wang, Min Tong, Yening Tan, Julian D. Down, Devon J. Shedlock, Eric M. Ostertag

MENU